This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
Kidney Cancer
RadiCal
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
FORT
NRG-GU 0101
Masofaniten (Oral EPI-7386)
RTIRE
SHORTER
SPLASH
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AMA Interim 2023
SUO 2023
ESMO 2023
IBCN 2023
ASTRO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2020
ASCO 2020
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2020 Kidney Cancer
Viewing 1-19 of 19 articles
ASCO 2020: PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704)
ASCO 2020: Discussant: Rare Variant Histologies in Renal Cell Carcinoma: Making the Unclear Be More Clear
ASCO 2020: Association of Gene Expression with Clinical Outcomes in Patients with Renal Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-427
ASCO 2020: Evaluation of Predictive Biomarkers for Nivolumab in Patients with Metastatic Clear Cell Renal Cell Carcinoma from the CheckMate-025 Trial
ASCO 2020: Phase II trial of Lenvatinib plus Pembrolizumab for Disease Progression after PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma
ASCO 2020: A Phase Ib Trial of Neoadjuvant/Adjuvant Durvalumab +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
ASCO 2020: COSMIC-313 Phase III Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Patients with Previously Untreated Advanced Renal Cell Carcinoma of Intermediate or Poor-Risk
ASCO 2020: Single Agent PD-1 Inhibitor Biomarkers in Untreated and Previously Treated Advanced RCC: What Can Biomarkers Teach Us to Advance Clinical Care?
ASCO 2020: A Phase III, Randomized, Placebo-Controlled Trial of Nivolumab or Nivolumab plus Ipilimumab in Patients with Localized Renal Cell Carcinoma at High-Risk of Relapse after Radical or Partial Nephrectomy (CheckMate 914)
ASCO 2020: Immunogenomic Characterization of Advanced Clear Cell Renal Cell Carcinoma Treated with PD-1 Blockade
ASCO 2020: Emerging Unmet Needs in RCC: An Ideal Sequential Strategy and the Post-Immunotherapy Space
ASCO 2020: Results from a Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer or Sporadic Papillary Renal Cell Cancer
ASCO 2020: KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma
ASCO 2020: Phase II Study of the Oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
ASCO 2020: FRACTION-RCC: Innovative, High-Throughput Assessment of Nivolumab + Ipilimumab for Treatment-Refractory Advanced Renal Cell Carcinoma
ASCO 2020: OMNIVORE: Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma
ASCO 2020: SAVOIR: A Phase III Study of Savolitinib versus Sunitinib in Patients with MET-Driven Papillary Renal Cell Carcinoma
ASCO 2020: Biomarker Analyses from the Phase III CheckMate 214 Trial of Nivolumab plus Ipilimumab or Sunitinib in Advanced Renal Cell Carcinoma
ASCO 2020: Biomarkers of Single-Agent versus Combination Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free